SI2822939T1 - Kondenzirani biciklični derivati 2,4-diaminopirimidina kot dvojni zaviralec alk in fak - Google Patents
Kondenzirani biciklični derivati 2,4-diaminopirimidina kot dvojni zaviralec alk in fakInfo
- Publication number
- SI2822939T1 SI2822939T1 SI201330151T SI201330151T SI2822939T1 SI 2822939 T1 SI2822939 T1 SI 2822939T1 SI 201330151 T SI201330151 T SI 201330151T SI 201330151 T SI201330151 T SI 201330151T SI 2822939 T1 SI2822939 T1 SI 2822939T1
- Authority
- SI
- Slovenia
- Prior art keywords
- fused bicyclic
- fak inhibitor
- diaminopyrimidine derivative
- dual alk
- alk
- Prior art date
Links
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 title 1
- 229940124783 FAK inhibitor Drugs 0.000 title 1
- -1 bicyclic 2,4-diaminopyrimidine derivative Chemical class 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607305P | 2012-03-06 | 2012-03-06 | |
| PCT/US2013/029304 WO2013134353A1 (en) | 2012-03-06 | 2013-03-06 | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor |
| EP13710258.8A EP2822939B1 (en) | 2012-03-06 | 2013-03-06 | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2822939T1 true SI2822939T1 (sl) | 2016-04-29 |
Family
ID=47892060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201330151T SI2822939T1 (sl) | 2012-03-06 | 2013-03-06 | Kondenzirani biciklični derivati 2,4-diaminopirimidina kot dvojni zaviralec alk in fak |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US9132128B2 (https=) |
| EP (2) | EP2822939B1 (https=) |
| JP (2) | JP6016953B2 (https=) |
| KR (1) | KR102068374B1 (https=) |
| CN (2) | CN106166155B (https=) |
| AU (1) | AU2013229995B2 (https=) |
| CA (1) | CA2865420C (https=) |
| CL (1) | CL2014002353A1 (https=) |
| CY (1) | CY1117565T1 (https=) |
| DK (1) | DK2822939T3 (https=) |
| EA (2) | EA033124B1 (https=) |
| ES (2) | ES2681487T3 (https=) |
| HR (1) | HRP20160387T1 (https=) |
| HU (1) | HUE027976T2 (https=) |
| IL (2) | IL234239A (https=) |
| ME (1) | ME02460B (https=) |
| MX (2) | MX372740B (https=) |
| MY (1) | MY177290A (https=) |
| NZ (1) | NZ630251A (https=) |
| PH (1) | PH12014501979B1 (https=) |
| PL (1) | PL2822939T3 (https=) |
| RS (1) | RS54689B1 (https=) |
| SG (2) | SG11201405371PA (https=) |
| SI (1) | SI2822939T1 (https=) |
| SM (1) | SMT201600134B (https=) |
| UA (1) | UA115052C2 (https=) |
| WO (1) | WO2013134353A1 (https=) |
| ZA (1) | ZA201406147B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS54689B1 (sr) * | 2012-03-06 | 2016-08-31 | Cephalon, Inc. | Spojeni biciklični 2,4- diaminopirimidin derivat kao dualni alk i fak inhibitor |
| SG11201608303QA (en) | 2014-04-04 | 2016-11-29 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| MX2017008430A (es) * | 2014-12-23 | 2018-03-23 | Cephalon Inc | Métodos para preparar derivados de 2,4-diaminopirimidina bíclica fusionada. |
| CA3108236A1 (en) | 2018-08-07 | 2020-02-13 | In3Bio Ltd. | Methods and compositions for inhibition of egf/egfr pathway in combination with anaplastic lymphoma kinase inhibitors |
| WO2024178339A2 (en) * | 2023-02-23 | 2024-08-29 | The Regents Of The University Of Michigan | Methods for treating neuroblastoma with a dual anaplastic lymphoma kinase and focal adhesion kinase inhibitor |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1648455A4 (en) | 2003-07-23 | 2009-03-04 | Exelixis Inc | MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE |
| PT1660458E (pt) | 2003-08-15 | 2012-04-27 | Novartis Ag | 2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário |
| CN1918158B (zh) * | 2004-02-14 | 2011-03-02 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| JP2008502595A (ja) | 2004-03-31 | 2008-01-31 | エグゼリクシス， インコーポレイテッド | 未分化リンパ腫キナーゼモジュレータおよびその使用方法 |
| ES2622493T3 (es) * | 2006-02-24 | 2017-07-06 | Rigel Pharmaceuticals, Inc. | Composiciones y métodos para la inhibición de la ruta de JAK |
| ES2555803T3 (es) | 2006-10-23 | 2016-01-08 | Cephalon, Inc. | Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met |
| NZ577197A (en) * | 2006-12-08 | 2011-02-25 | Irm Llc | Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors |
| CN101678215B (zh) * | 2007-04-18 | 2014-10-01 | 辉瑞产品公司 | 用于治疗异常细胞生长的磺酰胺衍生物 |
| ES2575084T3 (es) * | 2009-06-10 | 2016-06-24 | Chugai Seiyaku Kabushiki Kaisha | Compuesto tetracíclico |
| RS54689B1 (sr) * | 2012-03-06 | 2016-08-31 | Cephalon, Inc. | Spojeni biciklični 2,4- diaminopirimidin derivat kao dualni alk i fak inhibitor |
| KR101446742B1 (ko) * | 2012-08-10 | 2014-10-01 | 한국화학연구원 | Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| MX2017008430A (es) * | 2014-12-23 | 2018-03-23 | Cephalon Inc | Métodos para preparar derivados de 2,4-diaminopirimidina bíclica fusionada. |
-
2013
- 2013-03-06 RS RS20160238A patent/RS54689B1/sr unknown
- 2013-03-06 NZ NZ630251A patent/NZ630251A/en unknown
- 2013-03-06 MX MX2017006206A patent/MX372740B/es unknown
- 2013-03-06 PL PL13710258T patent/PL2822939T3/pl unknown
- 2013-03-06 UA UAA201410832A patent/UA115052C2/uk unknown
- 2013-03-06 CA CA2865420A patent/CA2865420C/en active Active
- 2013-03-06 KR KR1020147027590A patent/KR102068374B1/ko active Active
- 2013-03-06 AU AU2013229995A patent/AU2013229995B2/en active Active
- 2013-03-06 JP JP2014561069A patent/JP6016953B2/ja not_active Expired - Fee Related
- 2013-03-06 HR HRP20160387TT patent/HRP20160387T1/hr unknown
- 2013-03-06 WO PCT/US2013/029304 patent/WO2013134353A1/en not_active Ceased
- 2013-03-06 MX MX2014010613A patent/MX347772B/es active IP Right Grant
- 2013-03-06 CN CN201610591742.5A patent/CN106166155B/zh active Active
- 2013-03-06 SG SG11201405371PA patent/SG11201405371PA/en unknown
- 2013-03-06 EA EA201691574A patent/EA033124B1/ru not_active IP Right Cessation
- 2013-03-06 EA EA201491641A patent/EA025859B1/ru not_active IP Right Cessation
- 2013-03-06 SG SG10201507865QA patent/SG10201507865QA/en unknown
- 2013-03-06 EP EP13710258.8A patent/EP2822939B1/en active Active
- 2013-03-06 SI SI201330151T patent/SI2822939T1/sl unknown
- 2013-03-06 CN CN201380012764.6A patent/CN104159894B/zh active Active
- 2013-03-06 ME MEP-2016-68A patent/ME02460B/me unknown
- 2013-03-06 ES ES15202516.9T patent/ES2681487T3/es active Active
- 2013-03-06 ES ES13710258T patent/ES2570976T3/es active Active
- 2013-03-06 EP EP15202516.9A patent/EP3056494B1/en active Active
- 2013-03-06 DK DK13710258.8T patent/DK2822939T3/en active
- 2013-03-06 MY MYPI2014002428A patent/MY177290A/en unknown
- 2013-03-06 HU HUE13710258A patent/HUE027976T2/en unknown
-
2014
- 2014-08-21 IL IL234239A patent/IL234239A/en active IP Right Grant
- 2014-08-21 ZA ZA2014/06147A patent/ZA201406147B/en unknown
- 2014-09-02 US US14/474,928 patent/US9132128B2/en active Active
- 2014-09-05 CL CL2014002353A patent/CL2014002353A1/es unknown
- 2014-09-05 PH PH12014501979A patent/PH12014501979B1/en unknown
-
2015
- 2015-08-12 US US14/824,750 patent/US9339502B2/en active Active
-
2016
- 2016-05-04 US US15/146,164 patent/US9623026B2/en not_active Expired - Fee Related
- 2016-05-10 SM SM201600134T patent/SMT201600134B/it unknown
- 2016-05-10 CY CY20161100390T patent/CY1117565T1/el unknown
- 2016-09-27 JP JP2016188585A patent/JP2017039741A/ja active Pending
-
2017
- 2017-03-07 US US15/451,960 patent/US10111872B2/en active Active
- 2017-05-18 IL IL252364A patent/IL252364B/en active IP Right Grant
-
2018
- 2018-10-26 US US16/172,368 patent/US10632119B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252364B (en) | A fused bicyclic 2, 4-diaminopyrimidine derivative as a double alk and fak inhibitor | |
| IL272719B (en) | expansion joint | |
| PL2802240T3 (pl) | Złącze meblowe | |
| IL237126A (en) | Derivatives in cicadas | |
| ZA201406570B (en) | Novel fgfr3 fusion | |
| ZA201405045B (en) | Pyrazinecarboxamide compound | |
| ZA201407828B (en) | Bicyclic pyrazinone derivatives | |
| SG11201406860SA (en) | Quinazolinedione derivative | |
| PL4082524T3 (pl) | Preparaty triazynowe | |
| EP2887831A4 (en) | SHOE ARTICLES | |
| GB2505195B (en) | Joint configuration | |
| GB201218278D0 (en) | Translocating peptide | |
| AU2012905685A0 (en) | The Kangaroo Waterstorm | |
| AU4710P (en) | Fusion xTriticosecale | |
| GB201212160D0 (en) | Cyclone | |
| GB201220095D0 (en) | Structural joint | |
| GB201203314D0 (en) | Structural joint |